• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[冠状动脉疾病患者纤溶酶原激活物抑制剂活性增加导致纤溶能力下降]

[Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].

作者信息

Ihnken K, Speiser W, Müller-Berghaus G, Beyersdorf F, Schlepper M, Satter P

机构信息

Abteilung für Thorax-, Herz- und Gefässchirurgie, Johann Wolfgang Goethe-Universität Frankfurt am Main.

出版信息

Helv Chir Acta. 1992 Jan;58(4):503-8.

PMID:1582860
Abstract

The fibrinolytic capacity of the blood mainly depends on the amount of tissue-plasminogen activator (t-PA) antigen and plasminogen activator inhibitor (PAI). In this study the fibrinolytic response to a venous occlusion test (VOT) was measured in 109 patients with angiographically documented coronary artery disease (CAD) and in 20 healthy volunteers at comparable age (controls). CAD-patients had higher plasma plasminogen activator inhibitor capacity before (24.4 +/- 11.0 vs. 15.4 +/- 5.2 arbitrary units [AU/ml]; p less than 0.0002) and after VOT (19.6 +/- 13.2 vs. 10.9 +/- 5.3 AU/ml; p less than 0.0001) compared with controls. Furthermore they showed significant lower plasma t-PA activity after VOT (3.0 +/- 6.8 vs. 6.6 +/- 10.6 AU/ml; p less than 0.0001). However there were no difference between both groups in plasma t-PA antigen levels after VOT (17.3 +/- 12.1 vs. 18.7 +/- 14.4 ng/ml). In 10% of patients the decrease in fibrinolytic activity resulted from a lower t-PA release ("lower" was defined as mean minus one standard deviation of the control group). 40% showed elevated plasma PAI capacity before VOT ("elevated" was defined as mean plus two standard deviations of the control group). Both caused significantly reduced post occlusion plasma t-PA activity and prolonged Euglobulin clot lysis time (p less than 0.003). A positive correlation was found between PAI capacity and serum triglyceride levels. Reduced fibrinolytic activity in 109 patients with coronary heart disease based either on a decrease in t-PA antigen release or a increased in PAI capacity in comparison with healthy controls. The mechanism of these findings is not yet well-known.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

血液的纤溶能力主要取决于组织型纤溶酶原激活物(t-PA)抗原和纤溶酶原激活物抑制剂(PAI)的量。在本研究中,对109例经血管造影证实患有冠状动脉疾病(CAD)的患者和20名年龄相仿的健康志愿者(对照组)进行了静脉闭塞试验(VOT)后的纤溶反应测量。与对照组相比,CAD患者在VOT前(24.4±11.0对15.4±5.2任意单位[AU/ml];p<0.0002)和VOT后(19.6±13.2对10.9±5.3 AU/ml;p<0.0001)的血浆纤溶酶原激活物抑制剂能力更高。此外,他们在VOT后的血浆t-PA活性显著降低(3.0±6.8对6.6±10.6 AU/ml;p<0.0001)。然而,两组在VOT后的血浆t-PA抗原水平上没有差异(17.3±12.1对18.7±14.4 ng/ml)。10%的患者纤溶活性降低是由于t-PA释放减少(“减少”定义为对照组平均值减去一个标准差)。40%的患者在VOT前血浆PAI能力升高(“升高”定义为对照组平均值加上两个标准差)。两者均导致闭塞后血浆t-PA活性显著降低,优球蛋白凝块溶解时间延长(p<0.003)。PAI能力与血清甘油三酯水平之间存在正相关。与健康对照组相比,109例冠心病患者的纤溶活性降低,其原因要么是t-PA抗原释放减少,要么是PAI能力增加。这些发现的机制尚不清楚。(摘要截取自250字)

相似文献

1
[Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].[冠状动脉疾病患者纤溶酶原激活物抑制剂活性增加导致纤溶能力下降]
Helv Chir Acta. 1992 Jan;58(4):503-8.
2
Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.青少年血液纤溶成分的年龄依赖性以及低剂量口服避孕药对青少年凝血和纤溶的影响。
Thromb Haemost. 1988 Dec 22;60(3):361-4.
3
Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease.在年轻冠心病患者中,与体力应激试验相比,静脉闭塞后的纤溶反应。
Thromb Haemost. 1999 Sep;82 Suppl 1:80-4.
4
Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.酒精性肝硬化中的高纤溶状态:1型纤溶酶原激活物抑制物相对缺乏
Thromb Res. 2008;121(5):675-80. doi: 10.1016/j.thromres.2007.07.008. Epub 2007 Sep 17.
5
Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.有特发性深静脉血栓形成和/或肺栓塞病史患者的纤溶功能减退。
Thromb Haemost. 1992 Apr 2;67(4):397-401.
6
Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.使用单克隆抗组织型纤溶酶原激活剂抗体的组织型纤溶酶原激活剂抗原和功能联合检测系统评估纤溶能力。
J Lab Clin Med. 1987 Jun;109(6):665-71.
7
Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.正常男性和女性体内的纤溶酶原激活剂组织型纤溶酶原激活剂(t-PA)、尿激酶型纤溶酶原激活剂(u-PA)及其抑制剂(PAI) 。
Thromb Haemost. 1991 Nov 1;66(5):581-5.
8
Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.妊娠和产褥期静脉闭塞后的组织型纤溶酶原激活剂
Thromb Haemost. 1993 Sep 1;70(3):486-90.
9
A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.经皮腔内冠状动脉成形术成功后,纤溶酶原激活物抑制剂-1活性降低与冠状动脉再狭窄风险显著降低相关。
Thromb Haemost. 1992 Feb 3;67(2):209-13.
10
Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.正常受试者的纤维蛋白溶解——纤溶酶原激活物抑制剂与纤维蛋白溶解系统其他成分的比较
Thromb Haemost. 1988 Apr 8;59(2):299-303.